A Comparison of Automated Perfusion- and Manual Diffusion-Based Human Regulatory T Cell Expansion and Functionality Using a Soluble Activator Complex

Abstract

Absence or reduced frequency of human regulatory T cells (Tregs) can limit the control of inflammatory responses, autoimmunity, and the success of transplant engraftment. Clinical studies indicate that use of Tregs as immunotherapeutics would require billions of cells per dose. The Quantum® Cell Expansion System (Quantum system) is a hollow-fiber bioreactor that has previously been used to grow billions of functional T cells in a short timeframe, 8–9 d. Here we evaluated expansion of selected Tregs in the Quantum system using a soluble activator to compare the effects of automated perfusion with manual diffusion-based culture in flasks. Treg CD4+CD25+ cells from three healthy donors, isolated via column-free immunomagnetic negative/positive selection, were grown under static conditions and subsequently seeded into Quantum system bioreactors and into T225 control flasks in an identical culture volume of PRIME-XV XSFM medium with interleukin-2, for a 9-d expansion using a soluble anti-CD3/CD28/CD2 monoclonal antibody activator complex. Treg harvests from three parallel expansions produced a mean of 3.95 × 108 (range 1.92 × 108 to 5.58 × 108) Tregs in flasks (mean viability 71.3%) versus 7.00 × 109 (range 3.57 × 109 to 13.00 × 109) Tregs in the Quantum system (mean viability 91.8%), demonstrating a mean 17.7-fold increase in Treg yield for the Quantum system over that obtained in flasks. The two culture processes gave rise to cells with a memory Treg CD4+CD25+FoxP3+CD45RO+ phenotype of 93.7% for flasks versus 97.7% for the Quantum system. Tregs from the Quantum system demonstrated an 8-fold greater interleukin-10 stimulation index than cells from flask culture following restimulation. Quantum system–expanded Tregs proliferated, maintained their antigenic phenotype, and suppressed effector immune cells after cryopreservation. We conclude that an automated perfusion bioreactor can support the scale-up expansion of functional Tregs more efficiently than diffusion-based flask culture.

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

“…HF cartridges have been tested as cell proliferation chambers and demonstrated efficient expansion of adhesive cells, explained by a high inner surface area of the fibrils [ 32 ]. Interestingly, several studies also report the use of HFs for the expansion of suspension cells [ 33 , 34 ].…”

Membrane Applications in Autologous Cell Therapy

“…With full control of media flow rate, temperature and gas compositions afforded by the automatically fed cabinet, the Quantum system facilitates reduced manual operations thereby reducing the chance of contamination while improving reproducibility [73]. To date the platform has been used for, the expansion of CD3+ T-cell [75,76], MSCs [46,77], adipose stromal cells [78], neural stem cells [54], and iPSCs [79]. The DUET pump platform developed by FibreCellSystems is intended for laboratory scale HFBR systems.…”

Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

“…Gas transfer happens passively in static systems, which limits oxygen availability in high volume vessels, as the diffusive flux of a gas is inversely proportional to the thickness of the liquid that needs to be permeated, according to Fick’s law and the McMurtrey model of oxygen diffusion [ 60 ]. Oxygen transfer may be limited in non-perfused bioreactors because low agitation rates are required to minimize shear stress on the lymphocytes and headspace aeration is also generally preferred for the same reasons.…”